Work with thought leaders and academic experts in Cancer Research

Companies can greatly benefit from working with experts in the field of Cancer Research. These researchers bring a deep understanding of the disease and its mechanisms, allowing them to contribute valuable insights and expertise. Here are some ways companies can collaborate with academic researchers in Cancer Research: 1. Drug Discovery and Development: Academic researchers can assist in the discovery and development of new cancer drugs, providing expertise in target identification, preclinical testing, and clinical trials. 2. Biomarker Identification: Researchers can help identify biomarkers that can be used for early cancer detection, patient stratification, and monitoring treatment response. 3. Genomic Analysis: Experts in Cancer Research can analyze genomic data to identify genetic mutations and variations associated with cancer, enabling personalized treatment approaches. 4. Translational Research: Collaboration with academic researchers can facilitate the translation of basic research findings into clinical applications, bridging the gap between bench and bedside. 5. Clinical Trials: Companies can partner with academic researchers to conduct clinical trials, leveraging their expertise in trial design, patient recruitment, and data analysis. 6. Data Analytics: Researchers can apply advanced data analytics techniques to large-scale cancer datasets, uncovering patterns and insights that can inform treatment strategies. 7. Collaborative Research Projects: Joint research projects between companies and academic researchers can lead to innovative solutions and breakthrough discoveries in cancer treatment and prevention. 8. Education and Training: Academic researchers can provide educational programs and training to company employees, keeping them updated on the latest advancements in Cancer Research. 9. Intellectual Property: Collaboration with academic researchers can result in the generation of intellectual property, including patents and publications, which can enhance a company's competitive advantage. 10. Access to Networks and Resources: Academic researchers have access to extensive networks and resources, including collaborations with other experts, funding opportunities, and state-of-the-art facilities.

Researchers on NotedSource with backgrounds in Cancer Research include Ramy Ayoub, Dr. Michael W. Craige, PhD, MBA, Elena Shersher, Ph.D., John M Baust, Ph.D, Ping Luo, Dr. Everson A Nunes, Ph.D., Dr. Shilpa Patil, Ph.D, Elvira Forte, Dr. Lindsey Kuehm, Ph.D., Boris Leibovitch, and Michael W Harman.

Ramy Ayoub

Toronto, Ontario, Canada
PhD Medical Biophysics
Most Relevant Research Expertise
Cancer Research
Other Research Expertise (10)
neuro-oncology
mouse imaging
cancer therapy
normal tissue toxicity
Radiology, Nuclear Medicine and imaging
And 5 more
About
Ramy Ayoub is a highly educated and experienced individual in the field of Medical Biophysics. He obtained his Ph.D. in Medical Biophysics from the University of Toronto in 2023, where he developed a strong foundation in the principles and applications of this field. During his time at the University of Toronto, Ramy has been involved in conducting cutting-edge research in the field of Medical Biophysics, with a focus on developing new technologies and techniques to improve healthcare outcomes. Ramy's extensive education and experience have provided him with a deep understanding of the complexities of Medical Biophysics and the ability to apply his knowledge to real-world problems. He is passionate about using his skills and expertise to make a positive impact in the medical field and is dedicated to advancing the field of Medical Biophysics through his ongoing research and contributions.
Most Relevant Publications (2+)

7 total publications

QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY

Neuro-Oncology / Jun 01, 2018

Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634

MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma

Neuro-Oncology / Jun 01, 2022

Smith, K., Bihannic, L., Gudenas, B., Gao, Q., Haldipur, P., Tao, R., Iskusnykh, I., Chizhikov, V., Scoggins, M., Zhang, S., Edwards, A., Deng, M., Glass, I., Overman, L., Millman, J., Sjoboen, A., Hadley, J., Mankad, K., Onar-Thomas, A., … Northcott, P. (2022). MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 24(Supplement_1), i124–i125. https://doi.org/10.1093/neuonc/noac079.452

See Full Profile

Dr. Michael W. Craige, PhD, MBA

New York
Entrepreneurial Scientist | Research Technology, Informatics & Data Science
Most Relevant Research Expertise
Cancer Research
Other Research Expertise (5)
Biomedical Informatics
Computational Biology
Neuroinformatics
Bioinformatics
Oncology
About
Dr. Michael W. Craige is a research scientist and fellow, leveraging his expertise in biomedical informatics, data science, intellectual property law, and innovation strategy to assess patent, and license new inventions and technologies reported by scientists. He has contributed to publications in high-impact journals, such as Nature Communications and Frontiers in Oncology, and has helped several startups secure their first institutional venture capital funding. His professional journey encompasses a rich blend of roles, including an NSF I-Corps Startup Mentor at Rutgers Office of Innovation Ventures, his recent tenure as a Venture Capital Fellow at SOSV's IndieBio in New York, and training in intellectual property law as a patent agent at Casimir Jones Law Firm. Dr. Craige received his MBA from The Georgia Institute of Technology and his PhD in Biomedical Informatics at Rutgers University where he’s developing computational methods for high-throughput cancer genomic data analysis, including statistical models for elucidating the mechanisms of prostate cancer disease progression and therapeutic response. During his doctoral program, he focused his research on pediatric neurology to understand the underline molecular mechanism of epilepsy in infants, jointly at Emory and Rutgers University. Dr. Craige was the managing director and ex-founder at CiDrep Informatics, a health and scientific-informatics consulting firm, that operated across the US and Canada.
Most Relevant Publications (1+)

3 total publications

Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia

Frontiers in Oncology / Sep 06, 2023

Ramakrishnan, A., Datta, I., Panja, S., Patel, H., Liu, Y., Craige, M. W., Chu, C., Jean-Marie, G., Oladoja, A.-R., Kim, I., & Mitrofanova, A. (2023). Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1222168

See Full Profile

Elena Shersher, Ph.D.

Miami
Cancer researcher at University of Miami
Most Relevant Research Expertise
Cancer Research
Other Research Expertise (5)
Molecular Biology
Biochemistry
Cell Biology
Drug discovery
Cancer cell signaling
About
Elena Shersher, Ph.D. is a highly skilled and experienced biochemist with a strong background in cancer research. She received her Ph.D. in Biochemistry from Florida International University in 2016, where she was a recipient of a prestigious Presidential fellowship. After completing her Ph.D., Elena continued her career as a clinical program development lead and coordinator at a CRO. In 2017, Elena joined a cancer research team at the University of Miami as a researcher. In this role, she utilized her expertise in advanced laboratory techniques and data analysis to study the role of specific proteins in cancer cell signaling in order to identify promising molecular targets for therapeutic intervention. Elena's research has been published in several prestigious scientific journals, and she has presented her findings at numerous conferences. In addition to her research, Elena is also passionate about mentoring and teaching the next generation of scientists. She has served as a mentor and advisor to undergraduate and graduate students, helping them develop their research skills and guiding them in their academic and career paths. Elena's dedication and contributions to the field of cancer research have made her a valuable asset to the scientific community. With her expertise and experience, she continues to make significant advancements in understanding and treating cancer, bringing hope to those affected by this devastating disease.
Most Relevant Publications (2+)

4 total publications

Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells

Cancer Research / Apr 05, 2021

Alvarez-Trotta, A., Guerrant, W., Astudillo, L., Lahiry, M., Diluvio, G., Shersher, E., Kaneku, H., Robbins, D. J., Orton, D., & Capobianco, A. J. (2021). Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells. Cancer Research, 81(12), 3347–3357. https://doi.org/10.1158/0008-5472.can-20-3611

A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase

Molecular Therapy - Oncolytics / Mar 01, 2023

Diluvio, G., Kelley, T. T., Lahiry, M., Alvarez-Trotta, A., Kolb, E. M., Shersher, E., Astudillo, L., Kovall, R. A., Schürer, S. C., & Capobianco, A. J. (2023). A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase. Molecular Therapy - Oncolytics, 28, 307–320. https://doi.org/10.1016/j.omto.2023.02.008

See Full Profile

John M Baust, Ph.D

Ithaca, New York, United States of America
Proven success in delivering best-in-class services across scientific, commercial and education environments.
Most Relevant Research Expertise
Cancer Research
Other Research Expertise (16)
Cell Biology
Biotechnology
Biomedical Engineering
Transplantation
Surgery
And 11 more
About
***Proven success in delivering best-in-class services across highly regulated scientific and commercial environments.*** * Resourceful, dynamic, and future-focused professional; equipped with strategic leadership, business, research, and academic expertise with career excellence in conducting in-depth research, leading multi-faceted R&D projects, and developing new products and treatments. * Dedicated, driven self-starter focused on developing innovative life changing technologies and procedures advancing the areas of cancer treatment, regenerative medicine and cell therapy.   * Substantial experience in providing oversight for medical device development, pre-clinical studies, cancer therapy, stem cell preservation, cell therapy, tissue engineering, and organ transplantation, etc. * Astute at establishing solid relationships with stakeholders and industry leaders to drive innovative ideas and lead collaborative efforts in pursuit of accomplishing long-term milestones. * Successful in delivering interactive academic instruction across higher education settings offering captivating lectures on Biology and Entrepreneurship courses in accordance with the organizational mission. * Accredited with authoring, managing, and executing multi-million dollar grants, corporate contracts * Accomplished author of numerous patents and high profile publications to disseminate essential research findings.
Most Relevant Publications (13+)

68 total publications

Issues Critical to the Successful Application of Cryosurgical Ablation of the Prostate

Technology in Cancer Research & Treatment / Apr 01, 2007

Baust, J. G., Gage, A. A., Klossner, D., Clarke, D., Miller, R., Cohen, J., Katz, A., Polascik, T., Clarke, H., & Baust, J. M. (2007). Issues Critical to the Successful Application of Cryosurgical Ablation of the Prostate. Technology in Cancer Research & Treatment, 6(2), 97–109. https://doi.org/10.1177/153303460700600206

Cryoablation of Renal Cancer: Variables Involved in Freezing-Induced Cell Death

Technology in Cancer Research & Treatment / Apr 01, 2007

Clarke, D. M., Robilotto, A. T., Rhee, E., VanBuskirk, R. G., Baust, J. G., Gage, A. A., & Baust, J. M. (2007). Cryoablation of Renal Cancer: Variables Involved in Freezing-Induced Cell Death. Technology in Cancer Research & Treatment, 6(2), 69–79. https://doi.org/10.1177/153303460700600203

Development of a Tissue Engineered Human Prostate Tumor Equivalent for Use in the Evaluation of Cryoablative Techniques

Technology in Cancer Research & Treatment / Apr 01, 2007

Robilotto, A. T., Clarke, D., Baust, J. M., Van Buskirk, R. G., Gage, A. A., & Baust, J. G. (2007). Development of a Tissue Engineered Human Prostate Tumor Equivalent for Use in the Evaluation of Cryoablative Techniques. Technology in Cancer Research & Treatment, 6(2), 81–89. https://doi.org/10.1177/153303460700600204

Integrin involvement in freeze resistance of androgen-insensitive prostate cancer

Prostate Cancer and Prostatic Diseases / Jan 12, 2010

Baust, J. G., Klossner, D. P., VanBuskirk, R. G., Gage, A. A., Mouraviev, V., Polascik, T. J., & Baust, J. M. (2010). Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 13(2), 151–161. https://doi.org/10.1038/pcan.2009.59

Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model

Prostate Cancer and Prostatic Diseases / Jan 11, 2011

Santucci, K. L., Snyder, K. K., Baust, J. M., Van Buskirk, R. G., Mouraviev, V., Polascik, T. J., Gage, A. A., & Baust, J. G. (2011). Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. Prostate Cancer and Prostatic Diseases, 14(2), 97–104. https://doi.org/10.1038/pcan.2010.52

Temperature-dependent activation of differential apoptotic pathways during cryoablation in a human prostate cancer model

Prostate Cancer and Prostatic Diseases / Dec 11, 2012

Robilotto, A. T., Baust, J. M., Van Buskirk, R. G., Gage, A. A., & Baust, J. G. (2012). Temperature-dependent activation of differential apoptotic pathways during cryoablation in a human prostate cancer model. Prostate Cancer and Prostatic Diseases, 16(1), 41–49. https://doi.org/10.1038/pcan.2012.48

Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue

Prostate Cancer and Prostatic Diseases / Jan 27, 2015

Baust, J. G., Bischof, J. C., Jiang-Hughes, S., Polascik, T. J., Rukstalis, D. B., Gage, A. A., & Baust, J. M. (2015). Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue. Prostate Cancer and Prostatic Diseases, 18(2), 87–95. https://doi.org/10.1038/pcan.2014.54

Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation

Technology in Cancer Research & Treatment / Jun 23, 2016

Baumann, K. W., Baust, J. M., Snyder, K. K., Baust, J. G., & Van Buskirk, R. G. (2016). Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation. Technology in Cancer Research & Treatment, 16(4), 393–405. https://doi.org/10.1177/1533034616655658

Investigation of the Impact of Cell Cycle Stage on Freeze Response Sensitivity of Androgen-Insensitive Prostate Cancer

Technology in Cancer Research & Treatment / Jul 08, 2016

Santucci, K. L., Baust, J. M., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2016). Investigation of the Impact of Cell Cycle Stage on Freeze Response Sensitivity of Androgen-Insensitive Prostate Cancer. Technology in Cancer Research & Treatment, 15(4), 609–617. https://doi.org/10.1177/1533034616648059

Assessment of Cryosurgical Device Performance Using a 3D Tissue-Engineered Cancer Model

Technology in Cancer Research & Treatment / May 17, 2017

Baust, J. M., Robilotto, A., Snyder, K. K., Santucci, K., Stewart, J., Van Buskirk, R., & Baust, J. G. (2017). Assessment of Cryosurgical Device Performance Using a 3D Tissue-Engineered Cancer Model. Technology in Cancer Research & Treatment, 16(6), 900–909. https://doi.org/10.1177/1533034617708960

Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome

Technology in Cancer Research & Treatment / Jan 01, 2018

Baust, J. M., Rabin, Y., Polascik, T. J., Santucci, K. L., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2018). Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome. Technology in Cancer Research & Treatment, 17, 153303381876220. https://doi.org/10.1177/1533033818762207

Cryoablation: physical and molecular basis with putative immunological consequences

International Journal of Hyperthermia / Nov 29, 2019

Baust, J. G., Snyder, K. K., Santucci, K. L., Robilotto, A. T., Van Buskirk, R. G., & Baust, J. M. (2019). Cryoablation: physical and molecular basis with putative immunological consequences. International Journal of Hyperthermia, 36(sup1), 10–16. https://doi.org/10.1080/02656736.2019.1647355

Breast Cancer Cryoablation: Assessment of the Impact of Fundamental Procedural Variables in an In Vitro Human Breast Cancer Model

Breast Cancer: Basic and Clinical Research / Jan 01, 2020

Snyder, K. K., Van Buskirk, R. G., Baust, J. G., & Baust, J. M. (2020). Breast Cancer Cryoablation: Assessment of the Impact of Fundamental Procedural Variables in an In Vitro Human Breast Cancer Model. Breast Cancer: Basic and Clinical Research, 14, 117822342097236. https://doi.org/10.1177/1178223420972363

See Full Profile

Dr. Everson A Nunes, Ph.D.

Hamilton, Ontario, Canada
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Expertise
Cancer Research
Other Research Expertise (39)
skeletal muscle
nutrition
physical activity
obesity
cancer
And 34 more
About
Dr. Everson A Nunes is a highly accomplished researcher and educator in the field of physiological sciences. He received his Ph.D. in Cellular and Molecular Biology with a focus on Physiological Sciences from Universidade Federal do Paraná in 2009, after completing a BSc in Human Nutrition and an MSc in Physiological Sciences. He also holds a specialization in Exercise Physiology and a BSc in Biological Sciences from Universidade Federal do Paraná. Dr. Nunes has a strong background in research, having completed two post-doctoral fellowships at McMaster University and Universidade Federal do Paraná. He has also held positions as an associate professor and assistant professor at Universidade Federal de Santa Catarina. He has published numerous articles in peer-reviewed journals, and his research focuses on the effects of exercise and nutrition on physiological processes in the human body. In addition to his research, Dr. Nunes is also a dedicated educator. He has taught at various universities in Brazil, including Universidade Federal de Santa Catarina, Universidade Gama Filho, Faculdades Integradas Espírita, Pontificia Universidade Católica do Paraná, and Faculdade do Litoral Sul. He is known for his dynamic teaching style and his ability to engage students in complex physiological concepts. Dr. Nunes is a member of several professional organizations, including the American Society for Nutrition, the Canadian Society of Exercise Physiology, the Canadian Nutrition Society and the Brazilian Society of Physiology. He is also a regular speaker at national and international conferences, sharing his expertise and research findings with colleagues and students. Overall, Dr. Nunes is a highly qualified and experienced professional in physiological sciences, metabolism, cancer and nutrition. His dedication to research and education makes him a valuable asset to any institution.
Most Relevant Publications (6+)

97 total publications

Does Oil Rich in Alpha-Linolenic Fatty Acid Cause the Same Immune Modulation as Fish Oil in Walker 256 Tumor-Bearing Rats?

Nutrition and Cancer / Sep 21, 2016

Schiessel, D. L., Yamazaki, R. K., Kryczyk, M., Coelho de Castro, I., Yamaguchi, A. A., Pequito, D. C. T., Brito, G. A. P., Borghetti, G., Aikawa, J., Nunes, E. A., Naliwaiko, K., & Fernandes, L. C. (2016). Does Oil Rich in Alpha-Linolenic Fatty Acid Cause the Same Immune Modulation as Fish Oil in Walker 256 Tumor-Bearing Rats? Nutrition and Cancer, 68(8), 1369–1380. https://doi.org/10.1080/01635581.2016.1224364

Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer

Nutrition and Cancer / Dec 23, 2015

Camargo, C. de Q., Mocellin, M. C., Pastore Silva, J. de A., Fabre, M. E. de S., Nunes, E. A., & Trindade, E. B. S. de M. (2015). Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer. Nutrition and Cancer, 68(1), 70–76. https://doi.org/10.1080/01635581.2016.1115097

Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status

Nutrition and Cancer / Feb 24, 2015

Camargo, C. de Q., Borges, D. da S., Oliveira, P. F. de, Chagas, T. R., Del Moral, J. A. G., Durigon, G. S., Dias, B. V., Vieira, A. G., Gaspareto, P., Trindade, E. B. S. de M., & Nunes, E. A. (2015). Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status. Nutrition and Cancer, 67(3), 463–471. https://doi.org/10.1080/01635581.2015.1004732

Exercise and Shark Liver Oil Supplementation Reduce Tumor Growth and Cancer Cachexia in Walker 256 Tumor Bearing Rats

Journal of Cancer Science & Therapy / Jan 01, 2014

Bordignon, J. (2014). Exercise and Shark Liver Oil Supplementation Reduce Tumor Growth and Cancer Cachexia in Walker 256 Tumor Bearing Rats. Journal of Cancer Science & Therapy, 06(03). https://doi.org/10.4172/1948-5956.1000254

Bax/Bcl-2 Protein Expression Ratio and Leukocyte Function Are Related to Reduction of Walker-256 Tumor Growth After β-Hydroxy-β-Methylbutyrate (HMB) Administration in Wistar Rats

Nutrition and Cancer / Feb 01, 2012

Kuczera, D., Paro de Oliveira, H. H., Fonseca Guimarães, F. de S., de Lima, C., Alves, L., Machado, A. F., Coelho, I., Yamaguchi, A., Donatti, L., Naliwaiko, K., Fernandes, L. C., & Nunes, E. A. (2012). Bax/Bcl-2 Protein Expression Ratio and Leukocyte Function Are Related to Reduction of Walker-256 Tumor Growth After β-Hydroxy-β-Methylbutyrate (HMB) Administration in Wistar Rats. Nutrition and Cancer, 64(2), 286–293. https://doi.org/10.1080/01635581.2012.647229

Ratio of n6 to n-3 Fatty Acids in the Diet Affects Tumor Growth and Cachexia in Walker 256 Tumor-Bearing Rats

Nutrition and Cancer / Nov 01, 2005

Pizato, N., Bonatto, S., Yamazaki, R. K., Aikawa, J., Nogata, C., Mund, R. C., Nunes, E. A., Piconcelli, M., Naliwaiko, K., Curi, R., Calder, P. C., & Fernandes, L. C. (2005). Ratio of n6 to n-3 Fatty Acids in the Diet Affects Tumor Growth and Cachexia in Walker 256 Tumor-Bearing Rats. Nutrition and Cancer, 53(2), 194–201. https://doi.org/10.1207/s15327914nc5302_8

See Full Profile

Dr. Shilpa Patil, Ph.D

Vancouver, British Columbia, Canada
PhD & Postdoc level expertise in Cancer Research
Most Relevant Research Expertise
Cancer Research
Other Research Expertise (11)
Cancer
epigenetics
development
Oncology
Biophysics
And 6 more
About
Dr. Shilpa Patil is a highly experienced cancer researcher with a strong background in Preclinical studies. She received her Ph.D. in Molecular Medicine from the University of Göttingen in 2020, where she focused on developing novel treatments for pancreatic cancer. Prior to that, she completed her MSc in Regenerative Medicine from Manipal University in 2014 and her BSc in Biotechnology from the same institution in 2012. With over 6 years of research experience, Dr. Patil has worked at prestigious institutions such as the University of British Columbia, University of Göttingen and JNCASR. Her expertise lies in the areas of cancer biology, epigenetics, cell and molecular biology, and regenerative medicine. She has published numerous research articles in reputed journals and has presented her work at various international conferences. Dr. Patil is a dedicated and passionate scientist, committed to using her knowledge and skills to contribute to the fight against cancer. She is driven by her curiosity to unravel complex biological processes and her desire to make a positive impact in the field of cancer research. She is also driven to bridge the academia-industry gap.
Most Relevant Publications (3+)

20 total publications

EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6

Cancer Research / Nov 01, 2020

Patil, S., Steuber, B., Kopp, W., Kari, V., Urbach, L., Wang, X., Küffer, S., Bohnenberger, H., Spyropoulou, D., Zhang, Z., Versemann, L., Bösherz, M. S., Brunner, M., Gaedcke, J., Ströbel, P., Zhang, J.-S., Neesse, A., Ellenrieder, V., Singh, S. K., … Hessmann, E. (2020). EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Cancer Research, 80(21), 4620–4632. https://doi.org/10.1158/0008-5472.can-20-0672

TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer

Cancers / Jul 15, 2022

Versemann, L., Patil, S., Steuber, B., Zhang, Z., Kopp, W., Krawczyk, H. E., Kaulfuß, S., Wollnik, B., Ströbel, P., Neesse, A., Singh, S. K., Ellenrieder, V., & Hessmann, E. (2022). TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer. Cancers, 14(14), 3451. https://doi.org/10.3390/cancers14143451

HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells

Cancers / Dec 07, 2021

Ewers, K. M., Patil, S., Kopp, W., Thomale, J., Quilitz, T., Magerhans, A., Wang, X., Hessmann, E., & Dobbelstein, M. (2021). HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. Cancers, 13(24), 6163. https://doi.org/10.3390/cancers13246163

See Full Profile

Elvira Forte

New York, New York, United States of America
Scientific strategist • Senior Scientist • Senior Scientific Editor
Most Relevant Research Expertise
Cancer Research
Other Research Expertise (26)
fibrosis
inflammation
cardiomyopathies
Physiology
Cardiology and Cardiovascular Medicine
And 21 more
About
Motivated and growth-driven biomedical scientist with over 15 years of experience in the cardiovascular field. Strong background in cell and molecular biology, data analysis, and interpretation. Seeking #newopportunities to deliver value as a Senior Scientist, Associate Principal Scientist, Scientific Liaison, or Scientific Consultant within a company that combines new technologies such as single-cell omics and AI for drug discovery and personalized medicine. <br> Throughout my career, I've used various in vivo and in vitro models to investigate the molecular and cellular mechanisms of fibrosis and inflammation in the heart, and how these mechanisms are affected in mice with different genetic backgrounds. My experience includes project management and mentoring. I completed three projects involving international collaborations, supervised two junior researchers, and taught cellular and molecular techniques to at least six professionals. As one of the launching editors and senior editor at Nature Cardiovascular Research, I oversaw the quality of the content published in the journal and the editorial process. I collaborated with authors, reviewers, and editors to ensure the highest standards of scientific rigor, relevance, and innovation. I also contributed to the journal's vision, strategy, and outreach, promoting the latest advances and discoveries in the cardiovascular and hematology fields. This experience has sharpened my analytical and communication skills and broadened my understanding of the field, covering a wide range of studies, from basic research to clinical, epidemiological, and public health research. My mission is to advance the knowledge and practice of cardiovascular medicine and to bridge the gap between research and clinical applications. Keywords: cardiovascular, #fibrosis, inflammation, cardioimmunology, RNA, single-cell biology, #transcriptomics, imaging, animal models, small animal surgery, and scientific writing.
Most Relevant Publications (2+)

63 total publications

EMT/MET at the Crossroad of Stemness, Regeneration and Oncogenesis: The Ying-Yang Equilibrium Recapitulated in Cell Spheroids

Cancers / Jul 29, 2017

Forte, E., Chimenti, I., Rosa, P., Angelini, F., Pagano, F., Calogero, A., Giacomello, A., & Messina, E. (2017). EMT/MET at the Crossroad of Stemness, Regeneration and Oncogenesis: The Ying-Yang Equilibrium Recapitulated in Cell Spheroids. Cancers, 9(12), 98. https://doi.org/10.3390/cancers9080098

Cardiac Cell Therapy: The Next (Re)Generation

Stem Cell Reviews and Reports / Mar 25, 2011

Forte, E., Chimenti, I., Barile, L., Gaetani, R., Angelini, F., Ionta, V., Messina, E., & Giacomello, A. (2011). Cardiac Cell Therapy: The Next (Re)Generation. Stem Cell Reviews and Reports, 7(4), 1018–1030. https://doi.org/10.1007/s12015-011-9252-8

See Full Profile

Boris Leibovitch

New York, New York, United States of America
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Most Relevant Research Expertise
Cancer Research
Other Research Expertise (8)
Cell Biology
Developmental Biology
Molecular Biology
Hematology
Immunology
And 3 more
About
I am experienced molecular and cell biologist with deep genetics background who worked many years in USA and Russia on the bench and as teacher. Both types of work had demanded extremely broad knowledge and understanding of developments in the fields. Participation in grant writing, editorial/reviewer work for scientific journals and consulting colleagues on these subjects added a lot to my broad experience as the scientist.
Most Relevant Publications (2+)

22 total publications

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Molecular Cancer Therapeutics / Aug 01, 2015

Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., Sharma, R., Ariztia, E. V., Frankum, J., Brough, R., Sbirkov, Y., Ashworth, A., Lord, C. J., Zelent, A., Farias, E., … Waxman, S. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14(8), 1824–1836. https://doi.org/10.1158/1535-7163.mct-14-0980-t

Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1

Translational Oncology / Feb 01, 2022

Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320

See Full Profile

Michael W Harman

East Greenwich, RI, Rhode Island, United States of America
Distinguished Subject Matter Expert & Leader in Medical Technologies.
Most Relevant Research Expertise
Cancer Research
Other Research Expertise (13)
Bacteria & Cell Bio-Physics
Biomechanics
Infectious Diseases
Immunology
Microbiology
And 8 more
About
Highly skilled, energetic, and motivated professional empowered by over a decade of cross-disciplinary engineering and scientific applications experience. Presenting elegant solutions to prevalent biomedical challenges. Motivated by driving deliverable outcomes from complex research studies through effective leadership, active consulting work, and innovative problem-solving techniques. Seeking to make an immediate impact in a fast-paced biotechnology environment capitalizing on my advanced comprehension, continued professional growth, strategic product development expertise, and active network of personal connections across all areas of science, engineering, medicine, manufacturing and healthcare.
Most Relevant Publications (3+)

15 total publications

The induction of endoreduplication and polyploidy by elevated expression of 14-3-3γ

Genes &amp; Cancer / Dec 24, 2017

Gomes, C. J., Centuori, S. M., Harman, M. W., Putnam, C. W., Wolgemuth, C. W., & Martinez, J. D. (2017). The induction of endoreduplication and polyploidy by elevated expression of 14-3-3γ. Genes &amp; Cancer, 8(11–12), 771–783. https://doi.org/10.18632/genesandcancer.161

Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells

Cancer Research / Jul 15, 2016

Gomes, C. J., Harman, M., Centuori, S., Wolgemuth, C., & Martinez, J. (2016). Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells. Cancer Research, 76(14_Supplement), 3591–3591. https://doi.org/10.1158/1538-7445.am2016-3591

Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers

Cancer Research / Aug 01, 2015

Gomes, C. J., Harman, M., Martinez, J., & Centuori, S. (2015). Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers. Cancer Research, 75(15_Supplement), 2066–2066. https://doi.org/10.1158/1538-7445.am2015-2066

See Full Profile

Example Cancer Research projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on Cancer Research?

Development of Targeted Therapies

An academic researcher in Cancer Research can collaborate with a pharmaceutical company to develop targeted therapies for specific types of cancer. By leveraging their expertise in molecular biology and drug discovery, the researcher can contribute to the design and optimization of novel drugs that selectively target cancer cells while minimizing side effects.

Identification of Novel Biomarkers

A company specializing in diagnostic tools can collaborate with a Cancer Research expert to identify novel biomarkers for early cancer detection. The researcher can utilize their knowledge of cancer biology and molecular techniques to identify specific biomarkers that can be incorporated into diagnostic tests, enabling early intervention and improved patient outcomes.

Genomic Analysis for Personalized Medicine

By partnering with an academic researcher in Cancer Research, a biotech company can leverage genomic analysis to develop personalized medicine approaches. The researcher can analyze genomic data from patients to identify genetic mutations and variations that can inform treatment decisions, leading to more targeted and effective therapies.

Development of Immunotherapies

Collaboration between a pharmaceutical company and a Cancer Research expert can lead to the development of innovative immunotherapies. The researcher can contribute their knowledge of the immune system and cancer immunology to design and optimize immunotherapeutic approaches, enhancing the company's portfolio of cancer treatments.

Exploration of Combination Therapies

An academic researcher in Cancer Research can collaborate with a company to explore combination therapies for cancer treatment. By combining different drugs or treatment modalities, the researcher can help identify synergistic effects and optimize treatment regimens, potentially improving patient outcomes and expanding the company's treatment options.